TNF and rheumatic disorder: The newest anti-TNF-α agent is adalimumab (Humira, Abbott Pharmaceuticals Inc.), a recombinant human IgG1 monoclonal antibody targeting the TNF-α; adalimumab has been recently introduced for the treatment of RA,20 ankylosing spondylitis (AS),21 and psoriasis arthritis (PsA).22 Adalimumab is indicated for reducing the signs and symptoms of the joint involvement of rheumatic diseases, as well as for inhibiting the progression of structural damage in adult patients with moderately-to-severely active disease.